Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.

ABSTRACT:

Objective

Compare the effectiveness, tolerability, and safety of 3 months of weekly rifapentine and isoniazid under direct observation (3HP) versus 9 months of daily isoniazid (9H) in HIV-infected persons.

Design

Prospective, randomized, and open-label noninferiority trial.

Setting

The United States , Brazil, Spain, Peru, Canada, and Hong Kong.

Participants

HIV-infected persons who were tuberculin skin test positive or close contacts of tuberculosis cases.

Intervention

3HP versus 9H.

Main outcome measures

The effectiveness endpoint was tuberculosis; the noninferiority margin was 0.75%. The tolerability endpoint was treatment completion; the safety endpoint was drug discontinuation because of adverse drug reaction.

Results

Median baseline CD

SUBMITTER: Sterling TR 

PROVIDER: S-EPMC4899978 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature